Thermo Fisher’s Oncomine Dx Test Is First FDA Approved NGS-Based Companion Diagnostic To Detect Thyroid Cancers
The FDA approved Thermo Fisher Scientific Inc’s (NYSE:TMO) Oncomine Dx Target Test as a companion diagnostic (CDx) to select patients with RET-fusion…
FDA Approves First Branded Ocular Anesthetic In Almost 14 Years
The FDA approved Harrow Health Inc (NASDAQ:HROW) and Sintetica S.A’s Iheezo (chloroprocaine hydrochloride ophthalmic gel) 3% for ocular surface anesthesia. Iheezo is a…
FDA To Review Smaller Number Of Emergency Use Requests For COVID-19 Tests
The FDA said it will now review only a small number of emergency use authorization (EUA) requests for COVID-19 diagnostic…
Moleculin Biotech’s Potential Antiviral Compound Selected For NIAID-Funded Animal Studies
Moleculin Biotech Inc (NASDAQ:MBRX) announced that its WP1096 molecule would be evaluated in animal studies by the National Institute of Allergy…
Why Are Bellerophon Shares Jumping Today?
The FDA has accepted Bellerophon Therapeutics Inc’s (NASDAQ:BLPH) proposal to reduce the study size for its ongoing registrational REBUILD Phase 3…
NLS Pharmaceutics’ Shares Fall As Data From Narcolepsy Candidate Fails To Cheer Investors
NLS Pharmaceutics Ltd (NASDAQ:NLSP) announced topline results from its Phase 2a trial evaluating its lead product candidate, Quilience (Mazindol ER), in…
Seagen, Zai Lab Ink Regional Strategic Licensing Agreement For Cervical Cancer Treatment
Seagen Inc (NASDAQ:SGEN) and Zai Lab Limited (NASDAQ:ZLAB) have announced an exclusive collaboration and license agreement for the development and commercialization of TIVDAK…
Enalare Secures BARDA Award Of $50M For ENA-001 In Drug Overdose
Eagle Pharmaceuticals Inc (NASDAQ:EGRX) announced that Enalare Therapeutics Inc secured a contract for up to $50.3 million from the Biomedical Advanced Research and…
X4 Pharma Highlights New Data Supporting Mavorixafor’s Broad Potential In Chronic Neutropenia
X4 Pharmaceuticals Inc (NASDAQ:XFOR) announced new data from its Phase 1b trial evaluating the ability of its lead clinical candidate, mavorixafor,…